 NEW YORK and LONDON, Dec. 03, 2020 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Nasdaq: AKTX, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement andor leukotriene systems are implicated, today announces the publication of the results of a two-year research collaboration with the University College of London UCL Institute of Ophthalmology. The results showed that the therapeutic intravitreal IVT administration of long-acting nomacopan mitigated both the severity and progress of retinal damage in two models of autoimmune uveitis, a severe inflammatory eye disease where steroids are the primary treatment option. In addition, results showed the presence of inflammatory cells expressing both complement C5 and LTB4 receptors in retinal tissue from donor patients with uveitis as compared to healthy donor eyes. 